You are here

New Blood Test Can Aid in Evaluation of Concussion in Adults

Quick testing option may help reduce CT scans, radiation exposure

The FDA has permitted marketing of the first blood test to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion, in adults. The FDA reviewed and authorized the Banyan Brain Trauma Indicator (Banyan Biomarkers, Inc.) in less than six months as part of its Breakthrough Devices Program.

Most patients with a suspected head injury are examined using a neurological scale, called the 15-point Glasgow Coma Scale, followed by a computed tomography (CT) scan of the head to detect brain tissue damage, or intracranial lesions, that may require treatment. However, a majority of patients evaluated for mTBI/concussion do not have detectable intracranial lesions after having a CT scan.

Availability of a blood test for concussion will help health care professionals determine the need for a CT scan in patients suspected of having mTBI and help prevent unnecessary neuroimaging and associated radiation exposure to patients.

“Today’s action supports the FDA’s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging—an effort to ensure that each patient is getting the right imaging exam, at the right time, with the right radiation dose,” said FDA Commissioner Scott Gottlieb, MD. A blood test for mTBI/concussion, he added, “will likely reduce the CT scans performed on patients with concussion each year, potentially saving our health care system the cost of often unnecessary neuroimaging tests.”

According to the Centers for Disease Control and Prevention, in 2013 there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the U.S. Of these cases, TBI contributed to the deaths of nearly 50,000 people. TBI severity may range from mild to severe, with 75% of TBIs that occur each year being assessed as mTBIs or concussions. A majority of patients with concussion symptoms have a negative CT scan.

The Brain Trauma Indicator works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury. Levels of these blood proteins after mTBI/concussion can help predict which patients may have intracranial lesions visible by CT scan and which won’t. Being able to predict if patients have a low probability of intracranial lesions can help health care professionals in their management of patients and the decision to perform a CT scan. Test results can be available within three to four hours.

The FDA evaluated data from a multicenter, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product’s performance by comparing mTBI/concussion blood tests results with CT scan results. The Brain Trauma Indicator was able to predict the presence of intracranial lesions on a CT scan 97.5% of the time and those who did not have intracranial lesions on a CT scan 99.6% of the time.

These findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.

The Brain Trauma Indicator was reviewed under the FDA’s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.

Source: FDA; February 14, 2018.

More Headlines

More drugs or more costly drugs are being prescribed, industry trade group says
Risk approaches 13% for women who fall ill early in pregnancy
Alexion announces positive top-line results for ALXN1210 in PNH
Increased risk of high-frequency hearing loss pegged at 60%
Janssen drug targets metastatic urothelial cancer, marked by poor outcomes
Researchers say this real-world study in Canada should also apply to the U.S.
The results from a seven-year study were “entirely unexpected”
Generic competition pushed back to at least mid-2018
Report identifies critical need to minimize financial toxicity and increase access